Health Catalyst Financials - Benzinga

Health Catalyst Inc

HCATNASDAQ

Trade with Public

Trade with Public

$1.70

-0.03-1.73%

At close: Sep 11, 5:00 PM EST

$1.70

N/A

After Hours: 4:24 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Health Catalyst Financials

Health Catalyst (HCAT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Health Catalyst Shares Tumble Overnight: What Investors Need to Know

Health Catalyst stock fell after hours after reporting Q2 results and issuing weaker third-quarter revenue guidance.

Tanya Rawat

PRO
Health Catalyst Sees FY2026 Sales $246.000M-$249.000M vs $260.780M Est

Health Catalyst (NASDAQ:HCAT) sees FY2026 sales of $246.000 million-$249.000 million vs $260.780 million analyst estimate.

Benzinga Newsdesk

PRO
Health Catalyst Sees Q3 Sales $55.000M-$56.000M vs $62.159M Est

Health Catalyst (NASDAQ:HCAT) sees Q3 sales of $55.000 million-$56.000 million vs $62.159 million analyst estimate.

Benzinga Newsdesk

PRO
Health Catalyst Q2 Adj. EPS $0.04 Beats $0.03 Estimate, Sales $70.487M Beat $69.059M Estimate

Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.03 by 33.33 percent. This is unchanged from the same period last year. The company reported

Benzinga Newsdesk

PRO
Health Catalyst Sees Q2 Sales $68.000M-$70.000M vs $70.752M Est

Health Catalyst (NASDAQ:HCAT) sees Q2 sales of $68.000 million-$70.000 million vs $70.752 million analyst estimate.

Benzinga Newsdesk

PRO
Health Catalyst Q1 Adj. EPS $0.02, Inline, Sales $70.756M Beat $69.171M Estimate

Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The

Benzinga Newsdesk